Correction to: BMC Infect Dis (2020) 20:786
https://doi.org/10.1186/s12879-020-05507-4
Following publication of the original article [1], the author identified two errors in the Results section of the Abstract and in Table 2.
Table 2.
The relationship between study variables and mortality of patients with severe COVID-19
| Mortality | Unadjusted OR (95% CI) |
P-value | |||
|---|---|---|---|---|---|
| No | Yes | ||||
| Treatment Group | 24 (61.5) | 6 (30) | 0.27 (0.08, 0.85) | 0.025# | |
| Control Group | 15 (38.5) | 14 (70) | Ref | ||
| Age (years) | 54 (44, 60) | 60 (53.5, 70) | 1.05 (1.01, 1.1) | 0.014 | |
| Gender n (%) | Male | 27 (70) | 14 (70) | 0.96 (0.3, 3.12) | 0.951 |
| Female | 12 (30) | 6 (30) | Ref | ||
| HTN n (%) | 8 (23.3) | 5 (25) | 1.29 (0.36, 4.63) | 0.694 | |
| DM n (%) | 11 (20) | 5 (25) | 0.85 (0.25, 2.9) | 0.793 | |
| Chronic lung disease n (%) | 1 (6.6) | 1 (5) | 2 (0.12, 33.76) | 0.630 | |
| HR/min | 95 (90, 100) | 95 (89, 108) | 1.02 (0.96, 1.08) | 0.543 | |
| Systolic BP (mmHg) | 120 (120, 130) | 120 (110, 130) | 0.97 (0.93, 1.01) | 0.173 | |
| Diastolic BP (mmHg) | 80 (70, 80) | 70 (70, 80) | 0.95 (0.88, 1.01) | 0.120 | |
| RR /min | 19 (18, 22) | 20 (18, 22) | 0.98 (0.93, 1.04) | 0.545 | |
| BT C° | 37.1 (36.7, 37.7) | 37.1 (36.75, 37.65) | 1.26 (0.63, 2.52) | 0.518 | |
| O2 saturation (%) | 89 (87, 89) | 85 (80, 88) | 0.84 (0.74, 0.97) | 0.015 | |
| WBC (1000/mm3) | 5.1 (4.6, 7.4) | 7.2 (5.1, 11.2) | 1.00 (1.00, 1.00) | 0.743 | |
| Hb (g/dl) | 13.9 (12.6, 15) | 13.5 (12.05, 15.25) | 0.95 (0.8, 1.13) | 0.566 | |
| Plt (1000/mm3) | 210 (135, 247) | 172.5 (139.5, 193) | 1.00 (1.00, 1.00) | 0.090 | |
| LDH (U/L) | 520 (400, 687) | 761 (560.5, 1021) | 1.00 (1.00, 1.00) | 0.003 | |
| BUN (mg/dl) | 29 (25, 39) | 64 (50, 129.5) | 1.06 (1.02, 1.09) | 0.001 | |
| Creatinine (mg/dl) | 1 (1, 1.2) | 1.2 (1.1, 1.55) | 3.63 (0.95, 13.87) | 0.059 | |
| K (mEq/L) | 4 (3.7, 4.4) | 4.2 (4.1, 4.3) | 0.95 (0.8, 1.14) | 0.616 | |
| Na (mEq/L) | 138 (137, 139) | 138 (135, 143.5) | 1.04 (0.95, 1.14) | 0.344 | |
| ESR | 28 (20, 41) | 40 (26, 49.5) | 1.01 (0.99, 1.03) | 0.424 | |
| AST (U/L) | 31 (21, 39) | 29.5 (15.5, 52.5) | 1.00 (0.97, 1.02) | 0.735 | |
| ALT (U/L) | 34.5 (25, 41) | 38.5 (29.5, 48) | 1.01 (0.99, 1.02) | 0.306 | |
| BS (mg/dl) | 119 (105, 174) | 126 (109.5, 184) | 1.00 (0.99, 1.01) | 0.845 | |
| PaO2 (mmHg) | 46 (40, 50) | 39.5 (34, 49) | 0.92 (0.85, 0.99) | 0.035 | |
| PCO2 (mmHg) | 40 (35, 46) | 38 (36, 39.5) | 0.99 (0.91, 1.08) | 0.798 | |
| HCO3 (mEq/L) | 24 (22, 25) | 24.5 (19.5, 26.5) | 1.00 (0.89, 1.13) | 0.946 | |
| pH | 7.3 (7.3, 7.4) | 7.3 (7.2, 7.4) | 0.04 (0, 8.87) | 0.243 | |
The sentence currently reads:
“ The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively; P = 0.022). “.
The sentence should read:
“ The in-hospital mortality rate was significantly lower in the IVIg group compared to the control group (6 [20.0%] vs. 14 [48.3%], respectively; P = 0.025). “.
Furthermore, the correct Table 2 is given below.
The original article [1] has been corrected.
Contributor Information
Seyyed-Reza Sadat-Ebrahimi, Email: Sadatr@tbzmed.ac.ir.
Reza Hajizadeh, Email: hajizadh.reza@gmail.com.
Reference
- 1.Gharebaghi N, et al. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. 2020;20:786. doi: 10.1186/s12879-020-05507-4. [DOI] [PMC free article] [PubMed] [Google Scholar]